The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 08, 2024

Filed:

Jan. 29, 2021
Applicant:

Qaam Pharmaceuticals, Llc, Canandaigua, NY (US);

Inventor:

Steven A Rich, Canandaigua, NY (US);

Assignee:

QAAM Pharmaceuticals, LLC, Canandaigua, NY (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/438 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 9/70 (2006.01); A61K 31/165 (2006.01); A61K 31/4015 (2006.01); A61P 25/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/438 (2013.01); A61K 9/0053 (2013.01); A61K 9/4825 (2013.01); A61K 9/4866 (2013.01); A61K 9/7023 (2013.01); A61K 31/165 (2013.01); A61K 31/4015 (2013.01); A61P 25/28 (2018.01);
Abstract

The present invention includes a method for improving cognitive function in a human suffering from a neurodegenerative cognitive disorder. The method comprises administering to a patient a total daily dose of a cholinesterase inhibitor and a quaternary ammonium antimuscarinic compound. The total daily dose is divided into one or more doses administered before food intake. The quaternary ammonium antimuscarinic compound is administered in a first drug delivery element configured for rapid absorption into a body of the patient, and the cholinesterase inhibitor is administered in a second drug delivery element configured for a slower or delayed absorption into the body of the patient.


Find Patent Forward Citations

Loading…